US life sciences company Bio-Techne Corporation (NASDAQ: TECH) announced on Thursday that its spatial biology brand, Lunaphore, is partnering with Discovery Life Sciences (Discovery) to add Lunaphore COMET, a best-in-class spatial biology platform, to Discovery's global suite of biospecimen products and specialty lab services supporting customers with clinical research.
The partnership utilises Lunaphore's COMET technology, a fully-automated, high-throughput, hyperplex platform with tissue profiling capabilities, with Discovery's scientific expertise with the aim of advancing immuno-oncology, immunology, neuroscience and infectious disease research across all development stages at a new level of precision and speed.
Discovery says that its Lunaphore COMET Hyperplex Immunofluorescence Services will facilitate the development of next-generation assays for clinical trials and provide multidimensional spatial biology insights to advance biomarker discovery, patient stratification and translational medicine.
Discovery CEO Greg Herrema, said: "We are excited to expand our specialty lab services offering to include Lunaphore COMET Hyperplex Immunofluorescence Services. By integrating COMET with Discovery's molecular pathology expertise, this partnership is poised to drive biomedical research breakthroughs. This new service combined with our rigorous regulatory compliance processes will provide pharmaceutical companies with the ability to develop Clinical Laboratory Improvement Amendment (CLIA) compliant hyperplex tests."
Biophytis advances sarcopenia treatment with positive Phase 2 results
AstraZeneca secures EU approval for Imfinzi in limited-stage small cell lung cancer
BioSurfaces collaborates with Morphocell Technologies
iOncologi acquires TargImmune Therapeutics
Argent BioPharma announces positive CimetrA Phase IIb clinical trial results
Korro Bio receives FDA orphan drug designation for KRRO-110
SpliceBio doses first patient in Phase 1/2 ASTRA study of SB-007
Third Arc Bio reports first patient dosed in first-in-human study assessing ARC101
Amgen reports positive Phase 3 trial results for UPLIZNA in generalised myasthenia gravis
Celltrion launches STELARA biosimilar STEQEYMA in US market
Merck reports positive Phase 3 Data on HIV treatment DOR/ISL
Cantargia enrolls first patient in leukemia study with nadunolimab
Shilpa Medicare's Nor Ursodeoxycholic Acid Tablets IND receives regulatory approval in India